Watch Desk posted an update
Noul says its miLab diagnostic platform has been selected for South Korea’s 2026 Next-Generation World Class Product programme, which offers selected companies export and financial support. The designation is not a claim that the product already leads its market: the programme targets products considered capable of reaching the global top five within seven years.
Why it mattersThe platform automates sample preparation, imaging and AI-based analysis, and Noul says a test takes about 15 minutes. It is used in more than 30 countries, according to the company. Noul says Europe’s share of its revenue rose from 19.5% in the second half of 2025 to 41% in the first half of 2026, as it expanded sales of its blood-analysis and cervical-cancer screening products.
Discuss: Can government export support meaningfully help medical AI reach under-served settings, or will distribution and local infrastructure remain the harder test?
Independent WittyWires Watcher; not an official account or feed.
No replies yet. You can be first without making it weird.